- Home
- SPOK vs ENGN Comparison
SPOK vs ENGN Comparison
Compare SPOK & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- ENGN
- Stock Information
- Founded
- SPOK 2004
- ENGN 1999
- Country
- SPOK United States
- ENGN Canada
- Employees
- SPOK N/A
- ENGN N/A
- Industry
- SPOK Telecommunications Equipment
- ENGN
- Sector
- SPOK Telecommunications
- ENGN
- Exchange
- SPOK Nasdaq
- ENGN Nasdaq
- Market Cap
- SPOK 329.2M
- ENGN 297.7M
- IPO Year
- SPOK 1992
- ENGN N/A
- Fundamental
- Price
- SPOK $15.93
- ENGN $5.25
- Analyst Decision
- SPOK Hold
- ENGN Buy
- Analyst Count
- SPOK 1
- ENGN 9
- Target Price
- SPOK $15.00
- ENGN $25.22
- AVG Volume (30 Days)
- SPOK 155.3K
- ENGN 36.4K
- Earning Date
- SPOK 04-30-2025
- ENGN 03-10-2025
- Dividend Yield
- SPOK 7.85%
- ENGN N/A
- EPS Growth
- SPOK N/A
- ENGN N/A
- EPS
- SPOK 0.73
- ENGN N/A
- Revenue
- SPOK $137,653,000.00
- ENGN N/A
- Revenue This Year
- SPOK $3.51
- ENGN N/A
- Revenue Next Year
- SPOK N/A
- ENGN N/A
- P/E Ratio
- SPOK $21.82
- ENGN N/A
- Revenue Growth
- SPOK N/A
- ENGN N/A
- 52 Week Low
- SPOK $13.24
- ENGN $4.42
- 52 Week High
- SPOK $17.96
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- SPOK 42.34
- ENGN 42.54
- Support Level
- SPOK $15.52
- ENGN $4.90
- Resistance Level
- SPOK $16.86
- ENGN $5.60
- Average True Range (ATR)
- SPOK 0.42
- ENGN 0.52
- MACD
- SPOK -0.09
- ENGN 0.02
- Stochastic Oscillator
- SPOK 31.08
- ENGN 45.93
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.